Sees FY revenue $20.1B-$20.3B, consensus $20.2B. The company said it is on track to deliver its financial targets for 2025. Comments taken from slides being presented at the JPMorgan Healthcare Conference.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDX:
- Accelerate Diagnostics price target lowered to $2 from $5 at Craig-Hallum
- Becton Dickinson to pay $85M in infusion pump settlement
- Becton Dickinson granted exclusive license by Bactiguard for Foley catheters
- Becton Dickinson price target lowered to $280 from $310 at Morgan Stanley
- Becton Dickinson reports FDA safety communication doesn’t impact BD syringes
